1) Anterior disconnection syndrome and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Waugh interviews Drs. Ana Pereira and Alvardo Pascual-Leone about their paper on the anterior disconnection syndrome. Dr. Jennifer Fugate is reading our e-Pearl of the week about normal pressure hydrocephalus. In the next part of the podcast Dr. Alberto Espay interviews Dr. Richard Bedlack about his plenary session on contemporary clinical issues. The participants had nothing to disclose except Drs. Waugh, Pascual-Leone, Fugate, Espay and Bedlack.Dr. Waugh serves as an editorial board member of the Journal of Pediatric Biochemistry.Dr. Pascual-Leone serves on the scientific advisory board for Nexstim, NeoSync, Starlab, Neuronix, Allied minds and NovaVision, inc.; serves as an Associate Editor for European Journal of Neuroscience and Frontiers in Neuroscience; is listed as co-inventor in several patents related to real-time integration of TMS with EEG and functional imaging; receives research support from Nexstim, Neuronix, NIH, The Michael J. Fox Foundation, Berenson-Allen Foundation and RJG Family Foundation.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Bedlack serves on the scientific advisory board DSMB for the ceftriaxone ALS trial; serves on the speakers' bureau of Pfizer Inc, Eli Lilly and Company, Athena Diagnostics and Avanir Pharmaceuticals; is a consultant for Avanir Pharmaceuticals, Sanofi-aventis, Athena Diagnostics and UCB; receives research support from UCB, Biogen, Cytokinetics, Neuraltis and NIH. His clinic is sponsored by the ALS Association; and he is also involved in conducting clinical trials.